BBC vs FMED

Virtus Biotech Clinical Trials ETF against Fidelity Disruptive Medicine ETF: cost, size, returns, what they hold and how much of it is the same.

Overlap by weight
18%
32 shared positions
Fee gap
15 bp
FMED is cheaper
1-year return gap
14.4 pts
BBC is ahead
Larger fund
FMED
$52M

Side by side

BBCFMED
FundVirtus Biotech Clinical Trials ETFFidelity Disruptive Medicine ETF
IssuerVirtusFidelity
CategoryBiotech & Health InnovationInternet & Innovation
Expense ratio0.65%0.50%
Assets$40M$52M
Average daily dollar volume$1.2M$299K
ListedDec 16, 2014Apr 16, 2020
FrenzyCap score4544
1-month return−14.9%−1.2%
3-month return−15.7%+12.1%
Year to date+10.0%+18.3%
1-year return+35.0%+20.6%
30-day volatility42.1%28.9%
Worst drawdown, 1 year−30.2%−18.3%
Trailing 12-month yield1.54%—
Holdings13277
Top 10 weight11.8%34.4%
Look-through P/E——
Holdings vs fair value+21.7%−0.9%
Holdings above 200-day average37%78%
Net flow, latest 3 reported months+$5.1M thru Jul 2026−$17M thru May 2026
30-day implied volatility44.4%51.8%
Holdings as ofas of Jul 31, 2026SEC filingas of Oct 20, 2026issuer data

Returns are price returns and exclude distributions. Flows are each fund's own latest reported months and may not cover the same period.

Largest shared holdings

27% of BBC · 26% of FMED
HoldingBBCFMED
DFTX1.18%0.97%
AMLX0.93%1.31%
ORKA0.93%0.92%
RLAY0.85%0.98%
MBX1.24%0.83%
RVMD0.82%2.74%
KYMR0.80%1.86%
ELVN0.80%0.96%
COGT0.79%2.05%
VRDN0.78%1.35%
PRAX0.77%0.92%
PCVX0.76%1.99%
IRON0.76%1.06%
DNTH0.87%0.65%
XENE0.81%0.65%
STOK0.65%0.81%
NAMS0.61%0.70%
CTMX0.69%0.54%
ZBIO1.06%0.54%
TRAX1.67%0.52%
SYRE0.81%0.48%
PHVS0.71%0.42%
JANX0.75%0.39%
GPCR0.75%0.35%
CGON0.80%0.34%

Sector mix of the stock holdings

SectorBBCFMEDGap
Health Care90.2%74.6%+15.6%
Technology0.6%20.4%−19.7%

More: full overlap table · BBC holdings · FMED holdings

Fund data comes from each fund's SEC filings and issuer disclosures and is shown with the date it is as of. SEC portfolio and flow filings become public about 60 days after the period they cover. Nothing here is investment advice; see Terms.